10-KPeriod: FY2008

GILEAD SCIENCES, INC. Annual Report, Year Ended Dec 31, 2008

Filed February 27, 2009For Securities:GILD

Summary

Gilead Sciences, Inc.'s 2008 annual report (10-K) highlights a year of significant growth, with total revenues reaching $5.34 billion, a 36% increase from 2007. This growth was primarily driven by strong performance in antiviral products, particularly Truvada and Atripla, which collectively generated $4.67 billion in sales. The company also saw substantial growth in its Letairis product for pulmonary arterial hypertension. Gilead's strong financial position is underscored by its increasing cash reserves and a substantial stock repurchase program. The company continues to invest heavily in research and development, with R&D expenses rising to $721.8 million, reflecting its commitment to expanding its pipeline of innovative therapeutics. Despite the robust financial performance, Gilead faces ongoing risks and challenges. The company's heavy reliance on its HIV product portfolio makes it vulnerable to shifts in treatment paradigms and increased competition, including potential generic challenges. Furthermore, reliance on a few major wholesale distributors for U.S. sales, inventory management complexities, and the potential impact of international currency fluctuations present operational risks. The company is also navigating regulatory hurdles, as demonstrated by the FDA's request for an additional clinical study for aztreonam for inhalation solution. Gilead's proactive approach to managing these risks, including strategic collaborations and a focus on pipeline development, positions it for continued engagement in addressing unmet medical needs.

Financial Highlights

50 data points
Beta

Revenue

$5.34B

78.9% Gross Margin

Net Income

$1.98B

37.1% Net Margin

EPS (Diluted)

$1.03

Total Assets

$6.94B

Cash & Equivalents

$1.46B

Free Cash Flow

$2.14B

Financial Statements
Beta
Revenue$5.34B
Cost of Revenue$1.13B
Gross Profit$4.21B
SG&A Expenses$797.34M
Operating Expenses$2.66B
Operating Income$2.68B
Interest Expense$65.24M
Net Income$1.98B
EPS (Basic)$1.07
EPS (Diluted)$1.03
Shares Outstanding (Basic)1.84B
Shares Outstanding (Diluted)1.92B

Key Highlights

  • 1Total revenues grew by 36% to $5.34 billion in 2008, driven by strong antiviral product sales.
  • 2Antiviral product sales, led by Truvada and Atripla, increased by 36% to $4.67 billion.
  • 3Letairis sales showed substantial growth of 437% in 2008 due to its recent launch.
  • 4Research and Development (R&D) expenses increased by 22% to $721.8 million, indicating continued investment in pipeline development.
  • 5The company ended 2008 with $3.24 billion in cash, cash equivalents, and marketable securities, reflecting a strong liquidity position.
  • 6Gilead repurchased approximately $1.97 billion of its common stock under its $3.00 billion stock repurchase program in 2008.
  • 7The company faces significant competition in its key therapeutic areas, particularly HIV and Hepatitis B.

Frequently Asked Questions

Gilead Sciences' revenue growth in 2008 was primarily driven by its antiviral products, notably Truvada and Atripla, which saw significant sales increases. The company also experienced substantial growth in Letairis, a treatment for pulmonary arterial hypertension, and saw increases in AmBisome sales.

Key risks include a substantial portion of revenue being derived from HIV products, making the company vulnerable to changes in treatment paradigms or increased competition. Reliance on a few major U.S. wholesalers, inventory fluctuations, currency exchange rate volatility, and potential patent challenges are also significant concerns. Additionally, regulatory hurdles, such as the FDA's feedback on aztreonam for inhalation solution, pose risks to product commercialization.

Gilead Sciences is heavily investing in its R&D pipeline, with expenses increasing to $721.8 million in 2008. Key areas of focus include HIV therapeutics (with advancements in elvitegravir, GS 9350, and a fixed-dose regimen), Hepatitis C treatments (GS 9190 and GS 9450), cardiovascular treatments (daruSentan for hypertension and cicletanine for PAH), and respiratory treatments (aztreonam for inhalation solution). The company utilizes both internal development and strategic in-licensing and acquisitions to strengthen its pipeline.

Gilead Sciences demonstrated strong financial health at the end of 2008, with $3.24 billion in cash, cash equivalents, and marketable securities, and growing working capital. The company actively returned value to shareholders through a $3.00 billion stock repurchase program, repurchasing approximately $1.97 billion of its common stock during 2008. Gilead continues to prioritize R&D investment to fuel future growth.